WASHINGTON, Nov. 16 (TodayViralUSA) — The Food and Drug Administration has declined to approve ivonescimab, a closely watched lung cancer drug from Summit Therapeutics, ruling that the company had not shown it helps patients live longer — a setback for a medicine some analysts had billed as a potential rival to Merck’s blockbuster Keytruda.
Summit said Sunday that it received a complete response letter for its application seeking approval of ivonescimab plus platinum-based chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-small cell lung cancer whose disease had progressed after targeted EGFR inhibitor therapy.
Why the FDA said no
According to the company, the FDA concluded that substantial evidence of effectiveness was not established without a statistically significant improvement in overall survival, and that the drug’s benefit on progression-free survival alone did not support a favorable benefit-risk profile.
The application rested on the global Phase 3 HARMONi trial, which met its progression-free survival goal but showed only a positive trend on overall survival, its other primary endpoint. Summit said a later, post-hoc analysis with longer follow-up showed a consistent survival benefit across Asian and Western patients, with a hazard ratio of 0.76. The company said the safety profile was manageable, with no new safety signals.
“We are disappointed for patients and their families awaiting additional treatment options in this setting,” said Robert Duggan, Summit’s chairman and co-chief executive. He said the company’s belief in the drug was unchanged, citing five positive Phase 3 studies between Summit and its partner Akeso.
What it means
Ivonescimab is a bispecific antibody that blocks both PD-1, an immune checkpoint, and VEGF, which helps tumors grow blood vessels. Approval would have made it the first drug of its kind in the U.S. It was developed by China’s Akeso and has been on the market in China since 2024; Summit licensed rights to markets including North America and Europe in 2022.
The drug drew industry attention after it outperformed Keytruda in a head-to-head lung cancer trial in China, BioSpace reported. Summit did not outline next steps for the EGFR-mutated indication but said it is continuing late-stage trials in first-line lung cancer, colorectal cancer, bladder cancer and kidney cancer, along with combination studies with partners including AstraZeneca, GSK and Revolution Medicines.
Sources & Credits
- Summit Therapeutics: Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
- BioSpace: Summit’s PD-1xVEGF rejected by FDA in lung cancer
- OncLive: FDA Issues CRL to Ivonescimab Plus Chemo for Locally Advanced or Metastatic NSCLC
Image: Main entrance of FDA Building 1 at the agency’s White Oak campus in Silver Spring, Md., U.S. Food and Drug Administration photo, public domain, via Wikimedia Commons.




Join the conversation